Open AccessOptimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review
Author(s) -
Howard John Lim,
Ravi Ramjeesingh,
Dave Liu,
Vincent C. Tam,
Jennifer J. Knox,
Paul B. Card,
Brandon M. Meyers
Publication year - 2020
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djaa119
Subject(s) - sorafenib , regorafenib , medicine , lenvatinib , bevacizumab , oncology , ramucirumab , targeted therapy , hepatocellular carcinoma , atezolizumab , cabozantinib , clinical trial , nivolumab , cancer , overall survival , chemotherapy , immunotherapy , colorectal cancer
Systemic therapy for hepatocellular carcinoma (HCC) consisting of the tyrosine kinase inhibitor sorafenib has remained unchanged for over a decade, although results from phase III targeted therapy trials have recently emerged. This review considers available phase III evidence on the use and sequencing of targeted therapy for intermediate and advanced non-locoregional therapy (LRT) eligible HCC and discusses implications for clinical practice.